Prof Paul Chazot FBPhS is Director of the Durham University Wolfson Research Institute for Health and Wellbeing Pain Challenge Academy.
Paul has developed three new clinical development programmes over the last 20 years, one for chronic pain (Votucalis), one for Post-concussion syndrome, and one for Alzheimer’s Disease (PBM-T 1068nm), the former at the pipeline stage for the company Akari Therapeutics UK, and the latter two reaching the Phase 2 clinical stages in the US and UK. He is also the key academic collaborator for the Durham University spin-out company Nevrargenics, who has developed exciting new rational drug leads (RAR-M) for disease-modification in a range of neurodegenerative diseases (Ellorarxine).
Paul will be presenting Keynote 2: Optimising medicines using the GOTT study model, jointly with Frances Cole, at 1pm.
